REDEFINING

PRECISION MEDICINE

We believe that medicines should be developed with responder patients in mind from day one

Auransa has developed a data and AI-driven platform capable of ingesting complex human disease data, large and small, and use that data to understand the biology of complex diseases. We use our SMarTR Engine to study molecular disease subtypes and predict compounds and targets for responder patient populations. Many of the SMarTR Engine's predictions have gone beyond the computer to different phases of drug development.

See our pipeline.

Biology is complex

THE SMarTR ENGINE REVEALS BIOLOGY FROM DATA

Why limit ourselves to only well-known targets? We have the technology to discover drugs of novel pharmacology from vast amounts of genomics data collected from human disease tissues. We embrace complexity and heterogeneity.

THE SMarTR ENGINE IDENTIFIES PATIENTS TO MAXIMIZE RESPONSE

Failure of drug trials due to the wrong choice of patients is costly for everyone involved. We avoid that by understanding the responder patient population from the get-go.

THE SMarTR ENGINE FINDS THE RIGHT PRECLINICAL MODELS FOR THE RIGHT COMPOUNDS

It is important to smartly cross the preclinical chasm where we go from human data to animal models. Our AI engine can select the preclinical models that best match the molecular subtypes of diseases.

For maximum translational success.

DRUG DISCOVERY

Our specialty is working on highly intractable disease problems, with poorly understood biology and a lack of well-studied patient populations. Using the SMarTR Engine, we have created a pipeline of novel compounds that work uniquely, from drugging DNA such that there is specificity without damaging its structure, to finding a Goldilocks compound that can protect the heart from anthracycline-induced cardiotoxicity without impacting its efficacy.

PIPELINE OF NOVEL DRUGS

DISEASE AREA*
DISCOVERY
PRECLINICAL
CLINICAL
  • Hepatocellular carcinoma (HCC)

  • Acute myeloid leukemia (AML)

  • Breast cancer

  • Multiple myeloma

  • Prostate cancer

  • Small cell lung cancer (SCLC)

  • Cardioprotection

  • Multidrug resistant bacteria

  • Rheumatoid arthritis

  • NASH

  • Alzheimer's disease

  • COVID-19

  • *Among 30 diseases analyzed

Industry Leading Collaboration

Together we are stronger

  • loading
  • loading
  • loading
  • loading
  • loading
  • loading
  • loading
  • loading
  • loading
  • loading

leadership

It takes more than just a predictive engine
It takes the right team

Co-founder and CEO

Pek Lum, PhD

Pek Lum has more than 20 years of genomics and drug discovery experience. She is the chief architect of the science behind Auransa’s technology, combining her deep understanding of genomics and her vast experience in applying data science in the pharmaceutical industry.

Before founding Auransa, Pek was an early employee and vice president of Product and chief data scientist for Ayasdi, where she created early business verticals and helped grow the company from a few people to several dozen employees. Pek started off her career at Rosetta Inpharmatics, a pioneer in genomics and microarray technology. When Rosetta was acquired by Merck, Pek continued to champion the integration of data science into traditional biology, contributing to Merck’s development pipeline. While at Merck, Pek held roles of increasing responsibility, including leading molecular profiling for the diabetes, cardiovascular and obesity franchises. Pek received her Ph.D. in yeast genetics at the University of Washington, Seattle. Her work has been widely published in scientific and medical journals, such as Nature and Cell, and her research has contributed to discoveries in drug development and the understanding of complex diseases. She has previously served as an advisor to the Michael J. Fox Foundation for Parkinson’s Research and Resolution Bioscience, and is currently an advisor for Sequence Bio and Bayes Impact.

Co-founder and COO

Viwat Visuthikraisee, PhD

Viwat Visuthikraisee has more than 20 years of experience in software engineering, algorithm development and operations management. He oversees all aspects of operations at Auransa.

Viwat is a physicist turned entrepreneur. Before founding Auransa, he was a consulting operations manager and software architect specializing in supply chain logistics. He spent his early career at RAF Technology Inc., a computer vision and intelligent software company, where he learned to appreciate software design, algorithm development and building specialized databases for intelligent applications. Winning the prestigious Japanese Monbusho Scholarship, Viwat studied in Japan and received his B.S. and M.S. in Applied Physics from Hokkaido University and his Ph.D. in Theoretical Physics at the University of Washington, Seattle.

Chief Scientific Officer

Andy Protter, PhD

Andy Protter has more than 35 years of pharmaceutical industry experience working on preclinical research and development projects involving proteins, peptides and small molecules. At Auransa, he is responsible for all research, discovery and preclinical development activities.

Before joining Auransa, Andy held various R&D and business development leadership roles at Medivation and Scios Inc. (acquired by Johnson & Johnson), where he won the Johnson Medal for his work on Natrecor, a product approved for decompensated congestive heart failure. While at Medivation, Andy was responsible for preclinical pharmacology and toxicology of Enzalutamide, a drug approved for advanced prostate cancer, and he participated in the in-licensing of the phase III PARPx inhibitor Talazoparib. He also led the first successful cloning of apoB, the primary protein on LDL, and has participated in work described in more than 84 published papers, four book chapters and 28 patents. Andy earned a Ph.D. in Biochemistry from the State University of New York at Stony Brook.

VP, Medicinal Chemistry

Greg Luedtke, PhD

Greg has more than 20 years of small molecule drug discovery and development experience in a diverse range of disease areas. At Auransa he oversees all chemistry related activities.

Prior to joining Auransa Greg held leadership roles at Scios, Inc. (acquired by Johnson and Johnson) and Sai Life Sciences. While at Scios he was the Research Team Leader for their p38 kinase inhibitor program, which advanced two molecules into clinical trials (SCIO-469 and SCIO-323). At Sai Life Sciences he helped to establish their medicinal chemistry facility in Pune, India, managing 175 chemists engaged in a variety of drug discovery projects for global biotech and pharma companies. These outsourced drug discovery collaborations led to the advancement of numerous pre-clinical candidates.

Greg received his PhD in organic chemistry from Montana State University and completed a post-doctoral fellowship at Stanford University under the tutelage of Prof. W. S. Johnson.